GlassScriptPhysician profile
Vicki E Raab
NPI 1073600748
$25,600.01
in general payments reported to CMS, 2019-2025
24 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $3,043 · 2021: $5,319 · 2022: $8,520 · 2023: $4,290 · 2024: $3,462 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,038 · Food and Beverage: $2,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,037.50 |
| Food and Beverage | $2,391.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19,050.13 | 2021-2025 | |
| Allergan, INC. | $3,677.46 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $884.05 | 2019-2025 | |
| Pfizer INC. | $794.72 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $174.47 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $150.62 | 2020-2021 | |
| Alphatec Spine, INC | $143.99 | 2024 | Other - Miscellaneous |
| Biogen, INC. | $127.25 | 2022-2025 | Vumerity, Tysabri |
| Baxter Healthcare | $101.92 | 2022 | |
| Celgene Corporation | $87.29 | 2021-2023 | Zeposia |
| Upsher-Smith Laboratories LLC | $79.28 | 2019-2020 | |
| Amgen INC. | $61.49 | 2019-2021 | |
| Genentech USA, INC. | $41.14 | 2022-2023 | Ocrevus |
| Janssen Pharmaceuticals, INC | $39.29 | 2021 | |
| Lilly USA, LLC | $35.73 | 2023-2024 | Amyvid, Kisunla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $29.70 | 2020 | |
| Impel Pharmaceuticals INC. | $29.36 | 2023 | Trudhesa |
| Lundbeck LLC | $18.99 | 2024 | Rexulti |
| Avion Pharmaceuticals | $14.27 | 2022 | |
| Ucb, INC. | $13.79 | 2023 | Briviact |
| Teva Pharmaceuticals USA, INC. | $13.29 | 2019 | |
| Acorda Therapeutics, INC | $12.29 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.25 | 2020 | |
| Life Molecular Imaging LTD | $8.24 | 2024 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Raab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.